APA

Mac Lochlainn D. J., McKechnie D. G. J., Mehta A. B. & Hughes D. A. (20190114). The utility of the FIPI score in predicting long-term clinical outcomes in patients with Fabry disease receiving enzyme replacement therapy with agalsidase alfa. : Molecular genetics and metabolism.

Chicago

Mac Lochlainn Dylan J, McKechnie Douglas G J, Mehta Atul B and Hughes Derralynn A. 20190114. The utility of the FIPI score in predicting long-term clinical outcomes in patients with Fabry disease receiving enzyme replacement therapy with agalsidase alfa. : Molecular genetics and metabolism.

Harvard

Mac Lochlainn D. J., McKechnie D. G. J., Mehta A. B. and Hughes D. A. (20190114). The utility of the FIPI score in predicting long-term clinical outcomes in patients with Fabry disease receiving enzyme replacement therapy with agalsidase alfa. : Molecular genetics and metabolism.

MLA

Mac Lochlainn Dylan J, McKechnie Douglas G J, Mehta Atul B and Hughes Derralynn A. The utility of the FIPI score in predicting long-term clinical outcomes in patients with Fabry disease receiving enzyme replacement therapy with agalsidase alfa. : Molecular genetics and metabolism. 20190114.